← Research library

Glandokort: clinical report on a tissue-derived preparation

Comparison in people · 2011

What was studied
36 patients described; 26 controls separately stated. Enrollment denominator unresolved.
Main finding
In the adrenal-insufficiency table, plasma aldosterone was 38.5 versus 26.2 pg/mL after adjunctive Glandokort and conventional care, respectively. The subgroup sizes are unclear.

Plasma aldosterone in the adrenal-insufficiency table · 38.5 ± 1.3 pg/mL with Glandokort versus 26.2 ± 1.6 pg/mL with conventional care. Shared baseline 14.7 ± 1.2 pg/mL.

Reported findings and study design

The report mentions 36 patients and separately describes 26 controls. Assignment and subgroup sizes are unclear. The adjunctive schedule was one 10 mg capsule orally with meals twice daily (20 mg/day) for 30 days. The report excluded patients receiving hormone therapy.

Population or model 36 patients described; 26 controls separately stated. Enrollment denominator unresolved.

Results · Russian Medical Center report, PDF pages 32–33, Tables 1–2
MeasureResultComparison, timing and statistics
Plasma aldosterone in the adrenal-insufficiency table38.5 ± 1.3 pg/mL with Glandokort versus 26.2 ± 1.6 pg/mL with conventional care. Shared baseline 14.7 ± 1.2 pg/mL.
Cortisol in the prolonged-stress table431.4 ± 25.7 versus 311.4 ± 21.4 nmol/L. Shared baseline 287.5 ± 18.5 nmol/L.
ACTH in the prolonged-stress table28.6 ± 1.1 versus 17.4 ± 1.3 pg/mL. The table gives no significance mark for ACTH.

The tables mark aldosterone and cortisol as significant against conventional care. Subgroup sizes and the relationship of the 26 controls to the 36 described patients are unclear.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • Resolve enrollment and diagnostic criteria before pooling participants. Hormone-marker changes cannot establish a treatment for nonspecific fatigue.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Source details

Institute report — commercial reproduction

Russian Medical Center report, PDF pages 32–33, methods and hormone tables.

Sources checked

Citation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Human comparative studyFull text available

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution). Glandokort: clinical report on a tissue-derived preparation Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards